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Abstract
Hedgehog signaling drives oncogenesis in several cancers and strategies targeting this pathway
have been developed, most notably through inhibition of Smoothened. However, resistance to
Smoothened inhibitors occurs via genetic changes of Smoothened or other downstream Hedgehog
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tcomponents. Here, we overcome these resistance mechanisms by modulating GLI transcription via
inhibition of BET bromodomain proteins. We show the BET bromodomain protein, BRD4,
regulates GLI transcription downstream of SMO and SUFU and chromatin immunoprecipitation
studies reveal BRD4 directly occupies GLI1 and GLI2 promoters, with a substantial decrease in
engagement of these sites upon treatment with JQ1, a small molecule inhibitor targeting BRD4.
Globally, genes associated with medulloblastoma-specific GLI1 binding sites are downregulated
in response to JQ1 treatment, supporting direct regulation of GLI activity by BRD4. Notably,
patient- and GEMM-derived Hedgehog-driven tumors (basal cell carcinoma, medulloblastoma and
atypical teratoid/rhabdoid tumor) respond to JQ1 even when harboring genetic lesions rendering
them resistant to Smoothened antagonists.
Keywords
Hedgehog; SHH; medulloblastoma; basal cell carcinoma; ATRT; BRD4; BET bromodomain;
GLI1; GLI2; epigenetics; JQ1
Introduction
The Hedgehog (Hh) pathway is an evolutionarily conserved signaling axis that directs
embryonic patterning through strict temporal and spatial regulation of cell proliferation and
differentiation1. Developmental aberrations in Hh signaling result in dysmorphology, such
as cyclopism, holoprosencephaly and limb deformity when its output is absent or
decreased2, and cancer predisposition as is seen in Nevoid basal cell carcinoma syndrome
(Gorlin syndrome)3 when its output is increased or unchecked1,4.
In canonical Hh signaling, several morphogens (SHH, IHH, DHH)5,6 have been identified
that bind to the multi-pass cell surface receptor Patched (PTCH1)1. When not bound by Hh
ligand, PTCH1 inhibits the G protein-coupled receptor, Smoothened (SMO)7. Once bound
by ligand, however, PTCH1 no longer inhibits SMO, allowing SMO to positively regulate
mobilization of the otherwise latent zinc-finger transcription factor GLI2, residing in the
cilia, to the nucleus where GLI2 transactivates the GLI1 promoter8-10. GLI1 and GLI2
directly transactivate transcription of Hh target genes, several of which are involved in
proliferation, such as MYCN and CCND111. GLI1 also serves to amplify the output of Hh
signaling in a positive feedback loop by activating transcription of GLI2, albeit indirectly12.
Ultimately, the transcriptional programs mediated by Hh signaling orchestrate an array of
events based on cellular, temporal and spatial context, with perhaps the most phenotypically
consequential being an increase in cell proliferation.
Inappropriate activation of Hh signaling results in tumor formation in several tissue lineages,
including skin, brain, muscle, breast and pancreas13-15. The tumors most commonly
associated with aberrant Hh signaling are basal cell carcinoma (BCC) and medulloblastoma,
given their prevalence in individuals with germline mutations in PTCH1 (Gorlin
syndrome)3,4. However, the overwhelming majority of Hh-driven BCCs and
medulloblastomas activate Hh signaling through sporadic somatic mutations in PTCH1 or
others components of the Hh pathway14,16,17. These include activating mutations in SMO or
inactivating mutations in SUPPRESSOR OF FUSED (SUFU), which negatively regulates
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tHh output downstream of SMO17,18. Genomic amplification of GLI2, and more rarely GLI1,
has also been reported and is associated with a more aggressive clinical course16,19-21. In
addition, non-canonical activation of the Hh pathway can occur through loss of SMARCB1,
a component of the SWI/SNF chromatin remodeling complex, which results in de-repression
of transcriptional activity at the GLI1 locus in malignant rhabdoid tumors22. Similarly, the
EWS/FLI fusion oncogene responsible for Ewing sarcoma has been show to directly
transactivate the GLI1 promoter23.
The identification of SMO as the main pharmacological target of cyclopamine24, a natural
compound found in wild corn lily (Veratrum californicum)2, fostered the development of
clinically optimized compounds with potent activity against SMO25-27. Some of these
compounds have shown clinical efficacy against basal cell carcinoma, medulloblastoma and
other cancers28-30. However, emergence of resistance and a priori resistance have been
encountered25,29,31, prompting investigations into alternate strategies targeting novel sites
on SMO and Hh pathway components downstream of SMO32,33 or signaling pathways that
cooperate with Hh activation in development and disease34,25,35. High-throughput screens
have also identified novel scaffolds that regulate GLI processing and its translocation to/
from the cilia and nucleus36. However, the effectiveness of these strategies against Hh-
driven cancers with MYCN-amplification is unclear as N-MYC appears to be epistatic to the
targets of many of these drugs.
A novel class of drugs targeting bromo and extra C-terminal (BET) bromodomain proteins
(BRD2-4, BRDT) has been recently described37. Bromodomains recognize and bind to ε-N-
lysine acetylation motifs on open chromatin, such as those found on K27 residues of H3
histone N-terminal tails38,39. The BET proteins also interact with the positive transcription
elongation factor (P-TEFb)40,41 and phosphorylate serine2 of RNA polymerase II,
facilitating gene transcription at “super-enhancer” sites across the genome42,43. BRD-
containing complexes that bind at these super-enhancers often localize to promoter regions
of key transcription factors such as MYC, and disruption of these complexes by BET
inhibitors have produced significant responses in mice bearing xenografts of treatment-
refractory cancers driven by MYC and other previously ‘”untargetable” oncogenes, with
limited or no toxicity to normal tissues44-47.
Here, we hypothesized that BET inhibitors provide a rational strategy for treating Hh-driven
tumors, including those resistant to SMO antagonists. We provide evidence that BRD4 is a
critical regulator of GLI1 and GLI2 transcription through direct occupancy of their
promoters. Furthermore, we show that occupancy of GLI1 and GLI2 promoters by BRD4
and transcriptional activation at cancer-specific GLI promoter-binding sites are markedly
inhibited by the BET inhibitor, JQ1. In GEMM and patient-derived tumors with constitutive
Hh pathway activation, JQ1 effectively decreases tumor cell proliferation and viability in
vitro and in vivo, even when genetic lesions conferring resistance to SMO inhibitors (SMO
inhibitors) are present. Remarkably, the inhibition of cell proliferation by JQ1 can be
rescued by plasmid-driven expression of GLI2, which is not under direct transcriptional
regulation by BET proteins. In sum, our study identifies BET proteins as novel epigenetic
regulators of Hedgehog transcriptional output, and establishes rationale for the use of BET
inhibitors in cancers with evidence of Hh pathway activation.
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BRD4 is required for ligand-induced Hedgehog transcriptional output
The BET protein BRD4 enhances transcription of key genes involved in embryonic stem
cell maintenance42 and oncogenesis43. Therefore, we hypothesized BRD4 is a
transcriptional co-factor for Hh-responsive genes. In the mouse 3T3 cell-based Hh-Light2
reporter line containing a stably integrated Gli-luciferase reporter construct48, ligand-
induced activation of Hh-Light2 cells with either Shh-N conditioned medium (CM)49 or
Smoothened agonist (SAG)48 resulted in an expected increase in Gli1-luciferase activity and
Gli1 mRNA levels, which were both potently inhibited by increasing doses of the BET
inhibitor, JQ1(Fig.1a;SuppFig.1). Upregulation of other Hh target genes such as Ptch1 and
Gli2 was also inhibited by JQ1(Fig.1b). In contrast, Smo was modestly influenced while
Sufu and Brd4 were not significantly altered by JQ1(Fig.1b). Notably, the inhibition of Gli1
by JQ1 equaled that of SMO inhibitors (GDC-0449, LDE225 or SANT-1)(Fig.1c,d).
Additionally, shRNA-mediated knockdown of Brd4 in Hh-Light2 cells followed by Shh-N
CM or SAG stimulation resulted in significant downregulation of ligand-induced Gli-
luciferase activity and Hh target gene expression, directly supporting an essential role of
Brd4 in Hh signaling(Fig.1e,f).
To further assess inhibition of Hh transcriptional output by JQ1, we utilized zebrafish
harboring a ptc2:GFP reporter transgene, a well-described canonical Hh pathway reporter in
zebrafish50,51. Embryos exposed to JQ1 from 2-30hpf, showed decreased expression of GFP
mRNAs similar to cyclopamine-exposed fish(Fig.1g). We also assessed whether JQ1 could
revert abnormal phenotypes caused by aberrant Hh signaling in a temperature-sensitive
transgenic fish line harboring an hsp70l:Shha-EGFP transgene51, which overexpresses Shh
and produces a reliable and well-described dysgenic eye phenotype that often includes a
ventral coloboma52,53. As predicted, heat-shocked transgenic fish treated with vehicle alone
(DMSO) developed abnormally shaped eyes with diminished diameter relative to their heat-
shocked non-transgenic sibs(Fig.1h). However, fish exposed to JQ1 immediately after heat
shock, trended towards more normal appearing eyes with statistically significant increases in
eye diameter, suggesting BET inhibition countered the effects of aberrant Hh signaling in
vivo(Fig.1h).
BRD4 regulates Hh signaling at the level of Gli1 and Gli2 promoters
We next examined JQ1's effects on Hh signaling in Sufu−/− mouse embryonic fibroblasts
(MEF)54 and Hh-Light2 cells overexpressing GLI2. SUFU positively regulates the
degradation of GLI proteins54, thus loss of SUFU activity results in stabilization of GLI and
constitutive Hh signaling downstream of SMO. As expected, we observed markedly
increased Gli1 mRNA and protein levels in Sufu−/− MEFs, which were substantially
downregulated by JQ1(Fig.2a,c;SuppFig.2a,b). Decreased Gli2 transcription, as well as Smo
to a lesser extent, was also noted after JQ1 treatment while Brd4 mRNA levels remained
unchanged(Fig.2a). In stark contrast to JQ1 treatment, little to no effect was observed in Gli
transcripts or Gli1 protein in Sufu−/− MEFs after treatment with the SMO inhibitors
(LDE225, GDC-0449 or SANT-1)(Fig.2b,c). Consistent with pharmacological inhibition of
Brd4, shRNA-mediated knockdown of Brd4 resulted in decreased Gli1 and Gli2 mRNA
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tlevels(Fig.2d). It is worth noting that Brd4 knockdown did not abrogate GLI-luciferase
activity or Gli expression as effectively as JQ1 treatment. This could be explained by
incomplete knockdown of Brd4, or suggests other BET proteins (all targets of JQ1) may also
contribute to the transcriptional regulation of Gli genes. Indeed, knockdown of either Brd2
or Brd3 resulted in significant decrease of Gli mRNAs in Sufu−/− MEFs(SuppFig.2c).
In Hh-Light2 cells, forced expression of full length murine Gli2 (HA-Gli2-FL) or an N-
terminally truncated active form of human GLI2 (Myc-GLI2-DN)55 resulted in increased
Gli1 mRNA level, which was inhibited by JQ1 but not by SMO inhibitors (GDC-0449,
LDE225 or SANT-1)(Fig.2e). Notably, we did not observe any decrease in ectopic GLI2
expression driven off the CMV promoter-expression construct after JQ1 treatment in
contrast to the marked decrease in endogenous Gli transcripts(Fig.2f;Fig.1b). Additionally,
upregulation of Ptch1, another Hh target gene, was not inhibited by JQ1, suggesting not all
Hh target genes are directly dependent on Brd4 as Gli genes themselves are(SuppFig.2d).
In Sufu−/− cells, JQ1 decreased Gli1 and Gli2 levels as early as 3h post-treatment, supporting
a role for Brd4 as a transcriptional cofactor that directly regulates transactivation of Gli
promoters(SuppFig.2e). Chromatin immunoprecipitation followed by quantitative PCR
(ChIP-qPCR) using anti-Brd4 antibody of regions flanking the transcription start sites of
Gli1 and Gli2 promoters confirmed increased Brd4 occupancy at both Gli promoters after
SAG-mediated activation of Hh signaling in Hh-Light2 cells(Fig.2g,h). Accordingly, ChIP-
qPCR with anti-PolII antibody showed engagement of both Gli promoters by PolII after
SAG stimulation. Notably, both Brd4 and PolII interactions at the Gli promoters were
blocked by the addition of JQ1(Fig.2g,h). Similarly, in Sufu−/− MEFs we documented
increased baseline occupancy of Gli promoters by Brd4 and PolII relative to wild type (WT)
MEFs, which were again markedly inhibited by JQ1(Fig.2i,j).
JQ1 inhibits Hh activity in Ptch-deficient medulloblastoma and basal cell carcinoma
We investigated the efficacy of JQ1 in Hh-driven tumors, utilizing cell lines derived from
autochthonous medulloblastomas (SmoWT-MB and Med1-MB) arising in Ptch+/−;Tpr53−/−
and Ptch+/−;lacZ mice, respectively32,56, and basal cell carcinoma (ASZ001)57, also derived
from Ptch+/− mice. JQ1 treatment resulted in marked downregulation of Gli mRNA and
protein expression with only little to no effect on Smo, Sufu or Brd4(Fig.3a-d;SuppFig.3a).
Again, a rapid decrease of Gli genes followed JQ1 treatment (as early as 3h), supporting a
direct effect of BET inhibition on Gli promoters(SuppFig.3b). Accordingly, ChIP-qPCR
using anti-Brd4 and anti-PolII antibodies showed potent inhibition of Brd4 and PolII
occupancy at Gli promoters in all cell lines upon exposure to JQ1(SuppFig.3c,d).
In Med1-MB and SmoWT-MB cells, JQ1 treatment resulted in dose-responsive decreases in
cell viability and to a much greater extent than in Hh-Light2 or Sufu−/− MEFs(SuppFig.4a).
Potent growth inhibition was achieved (IC50∼50-150nM;SuppFig.4b,c) with marked
decreases of proliferation(Fig.3e,f), induction of apoptosis(SuppFig.4d,e), and in Med1-MB
cells an increased fraction of cells in G1 and decreased fraction of cells transitioning through
S phase(SuppFig.4f). Notably, in SmoWT-MB cells, the inhibitory effects of JQ1 on Gli
expression, cell viability and proliferation were equivalent to that of SMO inhibitors
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t(GDC-0449 or LDE225)(Fig.3a,e,g;SuppFigs.3a,4d), and moreover, these effects were
enhanced when cells were exposed to both JQ1 and GDC-0449 in combination(SuppFig.4g).
JQ1 downregulates cancer-specific Gli1 targets in medulloblastoma
To assess shifts in global gene expression upon JQ1 treatment in Hh-driven
medulloblastoma, we generated gene expression microarray data from JQ1-treated SmoWT-
MB cells and DMSO- and GDC0449-treated cells as a comparison. We observed a
substantial overlap between significantly differentially expressed genes(p<0.0001) or gene
sets(p<0.0001) by JQ1 and GDC0449 in both cell lines, including anticipated GLI target
genes, Gli2, Ptch1, CCND1,2, Hhip and Cdk6(SuppFig.5a-c). We next compared JQ1 gene
expression profiles with gene sets derived from previously published ChIP-chip studies,
which indexed gene promoters with Gli1-binding sites in normal granule neuron precursor
cells (GNP) and Ptch+/− medulloblastoma cells58. Specifically, we analyzed for enrichment
of ChIP-chip peaks associated with GNPs, medulloblastoma, the overlap of both, and peaks
associated with GNPs alone or medulloblastoma alone(SuppTableS1). Gene sets enrichment
analysis (GSEA) revealed only genes with Gli1-promoter-binding sites associated with
medulloblastoma were significantly enriched in JQ1-treated cells(SuppFig.5d). These results
confirm the disruption of Gli1-mediated transcription by JQ1 and the preferential targeting
of cancer-specific Gli1 transcriptional activity in tumor cells43.
Brd4 knockdown decreases Hh signaling and proliferation, while ectopic GLI2 expression
rescues growth inhibition by JQ1
We tested whether knockdown of Brd4 could phenocopy the effects of JQ1 in Hh-driven
medulloblastoma cells. As expected, knockdown of Brd4 resulted in decreased Gli
expression(Fig.4a,b) and cell proliferation(Fig.4c,d), suggesting the inhibitory effect of JQ1
was through targeting of Brd4. Furthermore, to directly assess whether BET inhibition
blocked cell proliferation in Hh-driven tumor cells through targeting of Gli transcription, we
utilized plasmid-based expression of GLI2 (Myc-GLI2-DN;see Fig.2f) in SmoWT-MB cells
and monitored its ability to rescue the inhibition of proliferation by JQ1(Fig.4c).
Remarkably, ectopic expression of GLI2 negated the effects of JQ1 on EdU incorporation
and normalized levels to nearly the equivalent of DMSO-treated control. This indicated that
JQ1 inhibition of proliferation is mediated largely through inhibition of Gli transcription
and, intriguingly, that Brd4-independent transcriptional targets of Gli transcription factors
are sufficient to overcome BET inhibition(Fig.4e).
SMOi-resistant Hh-driven tumors are susceptible to BET inhibition
Given the documented mechanisms of resistance to current, clinically available SMO
inhibitors25,31 and the potential for BET inhibitors as a strategy to overcome this resistance,
we examined the efficacy of JQ1 in Hh-driven cancers with either acquired or a priori
resistance to SMO inhibitors(Fig.5a). We analyzed efficacy of JQ1 and SMO inhibitors
(GDC-0449 and LDE225) against medulloblastoma cells carrying an aspartate to glycine
substitution at amino acid residue 477 in Smo that results in decreased sensitivity to SMO
antagonists (SmoD477G-MB)(Fig.5b)32; patient-derived SUFU-mutated primary SHH
subtype medulloblastoma cells (RCMB025); patient-derived primary ATRT cells
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t(CHB_ATRT1, SU_ATRT2) with de-repression of GLI1 transcription via loss of SNF5/
SMARCB1/INI122; and patient-derived MYCN-amplified primary SHH subtype
medulloblastoma cells (RCMB018). Cell viability(Fig.5b–f,top panels), Gli/GLI levels(Fig.
5b-f,bottom panels) and EdU incorporation(SuppFig.6a-c) were markedly decreased in
response to JQ1, while little or no effect was observed with SMO inhibitors GDC-0449 or
LDE225. Additionally, Myc/MYC and Mycn/MYCN expression were examined in SmoWT-
MB, SmoD477G-MB, RCMB025, CHB_ATRT1 and RCMB018 with Mycn/MYCN
consistently inhibited by JQ1(Fig.5f, SuppFig.4h;SuppFig.6d–f), suggesting JQ1 targets at
least two significant driver oncogenes (GLI and N-MYC) in these tumors.
In vivo inhibition of Hh-driven tumors by JQ1
To support a therapeutic role for BET inhibition in Hh-driven tumors, we assessed the in
vivo efficacy of JQ1 against medulloblastomas and BCCs. We treated flank and intracranial
allografts of Med1-MB cells stably expressing a firefly luciferase reporter in NSG mice with
either JQ1(50mg/kg/d,IP) or vehicle control. We observed a significant reduction in flank
tumor growth in JQ1-treated mice, as well as an increase in overall survival in JQ1-treated
mice harboring intracranial allografts(Fig.6a,b and SuppFig.7a). Additionally,
medulloblastoma flank allografts with SmoWT-MB or SmoD477G-MB cells were treated
with vehicle control, JQ1(50mg/kg/d,IP) or GDC-0449(100mg/kg/d,PO). We observed
dramatic decreases in growth of SmoD477G-MB flank allografts in response to JQ1 but not
to GDC-0449, whereas SmoWT-MB flank allografts responded briskly to both GDC-0449
and JQ1(Fig.6c,d). To evaluate JQ1's efficacy against BCCs in vivo, we used an allograft
model of Ptch+/−;K14-creER2;p53flox/flox-derived mBCC cells34. JQ1 treatment(50mg/kg/
d,IP) resulted in significant growth inhibition of BCCs, but was not as effective as the
clinically-optimized SMO inhibitor, BMS-83329334(Fig.6e). Nonetheless, in all Hh-driven
tumor models tested, we observed reduction of Gli mRNA, regardless of whether allografts
were SMOi-sensitive or SMOi-resistant(SuppFig.7b–f). Together, these results demonstrate
in vivo efficacy of JQ1 against Hh-driven tumors, even those with acquired and a priori
resistance to clinically available SMO inhibitors.
Discussion
We have shown BRD4 and other BET proteins are critical regulators of GLI1 and GLI2
transcription and that BET inhibition provides a novel therapeutic strategy against Hh-driven
tumors. Importantly, since BET proteins regulate the far downstream transcriptional output
of Hh signaling, BET inhibition was effective against tumor cells that evade Smoothened
antagonists through mutation of SMO or amplification of nodes downstream of SMO(Fig.5).
Our study is clinically relevant for patients who have a priori resistance to SMO inhibitors
and to cases where emergence of resistance develops after initial response to such therapy.
By acting directly on the GLI1 and GLI2 promoters, BET inhibition circumvents all SMOi
resistance mechanisms that have been reported to date, which include mutations of SMO or
SUFU or amplifications in GLI2 or MYCN16,17,20,25,31. The response seen in MYCN-
amplified SHH medulloblastoma cells (RCMB018;Fig.5f) is similar to the recent study
showing efficacy of BET inhibitors in MYCN-amplified neuroblastoma46. We do observe,
however, Mycn/MYCN consistently downregulated by JQ1 in all Hh-driven models studied,
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role in directly transactivating the MYCN promoter.
Given the importance of Hh signaling in normal development, it will be essential to
understand and anticipate potential toxicities of BET inhibitor therapies as they enter into
clinical trials. Certainly, developmental anomalies were observed at very high doses of JQ1
in our zebrafish studies (data not shown), consistent with Brd4 heterozygous mice, which
display a multitude of defects that overlap with cyclopamine-treated or Hh-deficient
mice59,60. Of note, however, Brd4 heterozygous mice develop craniofacial but not overt
axial skeletal phenotypes59, unlike cyclopamine-exposed embryos2,60, suggesting lineage
specific differences of Hh pathway dependency on Brd4. Our finding that plasmid-driven
GLI2 expression can rescue the proliferation defect induced by JQ1, supports the existence
of GLI-responsive promoters that do not require BRD4 for their transactivation. Importantly,
such genes appear individually or collectively sufficient to mediate part, if not all, of the
oncogenic phenotype associated with Hh/GLI signaling.
Investigating how BRD4 regulates normal Hh-mediated biological processes and
documenting BRD4-related changes that occur during Hh-mediated oncogenic
transformation, could potentially elucidate factors essential for tumor development that are
independent of normal development. Our analysis of gene expression changes in JQ1-treated
medulloblastoma and BCC cells supports observations by Lee et al.58, who identified
significant shifts in Gli1 occupancy across the genome in medulloblastoma compared to
GNPs(SuppFig.5d). An unbiased characterization of Brd4 binding across the genome in
GNPs and medulloblastomas will clarify whether Brd4's genomic footprint overlaps with
Gli occupancy in the oncogenic state relative to the normal developmental state. Related to
this point, emerging evidence suggests BET proteins converge on “super-enhancer” sites
across the genome and that these super-enhancers help transactivate promoters of key
regulators of cellular identity in normal and pathogenic contexts42,43. Whether GLI
transactivates super-enhancer-related promoters and, accordingly, whether super-enhancers
are positioned over GLI promoters, is currently under active investigation.
Materials and Methods
Ethics statement
All studies were performed under approval and oversight by IRB committees of Stanford
University, Boston Children's Hospital and Rady Children's Hospital/Sanford-Burnham
Medical Research Institute.
Cell lines and drug reagents
Mouse BCC (ASZ001 and mBCC-SMOR3), 293T and Hh-Light2 cells were derived and
maintained as previously described24,34,57. RCMB025 and RCMB018 cells were derived
from primary surgical resections of two medulloblastoma cases at Rady Children's Hospital
and were further characterized by whole-genome sequencing as having a SUFU mutation
and MYCN amplification, respectively (Kool et al. Cancer Cell 2014, In press).
CHB_ATRT1 cells were derived from tumor obtained at the time of primary surgical
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tresection of a posterior fossa atypical teratoid/rhabdoid tumor at Boston Children's Hospital.
SU_ATRT2 cells were derived from tumor obtained at the time of surgical resection of an
intraventricular atypical teratoid/thabdoid tumor at Lucile Packard Children's Hospital/
Stanford University Medical Center. Med1-MB cells, generated from a spontaneous tumor
arising in a Ptch+/−;lacZ mouse, were kindly provided by Matthew Scott (Stanford).
SmoWT-MB and SmoD477G-MB cells isolated from either parental SmoWT or
SmoD477G mouse Ptch+/−; p53−/− MB hind-flank allografts were kindly provided by
Charles Rudin (Memorial Sloan-Kettering Cancer Center). Sufu−/− MEFs (conditional
deletion of exons 4-854) were kindly provided by Pao-Tien Chang (UCSF). SAG, SANT-1,
GDC-0449 (S1082, Vismodegib, HhAntag691) and LDE225 (S2151, NVP-LDE225,
Erismodegib) were purchased from SelleckChem.com. Shh-N conditional medium was
kindly provided by Philip Beachy (Stanford). JQ1 was synthesized as previously
described44.
RNA extraction and RT-qPCR
RNA was extracted using Qiazol Lysis Reagent (79306, Qiagen, Venlo, Netherland) per the
manufacturer's instructions. Reverse transcription was performed with 1ug total RNA using
the High Capacity cDNA Reverse Transcription Kit (4368813, Invitrogen). Real time qPCR
was performed using 2x Maxima SYBR Green qPCR Master Mix (#K0251, Thermo
Scientific) on an Eppendorf Mastercycler PCR machine. qPCR primers are listed in
Supplemental Table 2.
Cell cycle, proliferation, viability and apoptosis assays
For cell cycle analysis, cells were fixed in 70% ethanol for 30min at 4°C. After two washes
with cold PBS, fixed cells were resuspended in staining buffer (200ul PBS+10ul 1mg/ml PI
+2ul 100mg/ml RNase A) and incubated at 37°C for 45min. Cells were washed once with
cold PBS and filtered through 70uM mesh (ELKO Filtering Co., Maimi, FL, USA). Filtered
cells were centrifuged and resuspended in 500ul PBS for FACS analysis. Proliferation
assays were performed by culturing cells in the presence of 10uM EdU for 6-8hrs. The EdU
+ population was determined using either Click-iT EdU Alexa Fluor 488 Flow Cytometry
Assay Kit (C35002, Invitrogen, CA, USA) or Click-iT EdU Alexa Fluor 594 Imaging Kit
(C10339, Invitrogen, CA, USA). Cells were counter-stained with DAPI (D8417, Sigma,
MO, USA) and the proliferation index calculated as EdU+/DAPI+ cells. Apoptosis was
analyzed using BD Pharmingen FITC Annexin V Apoptosis Detection kit I (Cat# 556547,
BD Biosciences, CA, USA) per the manufacturer's instructions. Cell viability was assessed
using CellTiter-Glo (G7573, Promega, WI, USA) according to the manufacturer's
instructions. Cells were plated at 5000 cells/well in 96-well plates, treated with drugs as
indicated and data collected on a TECAN Infinite 200 plate reader. The drug synergy
between JQ1 and GDC-0449 was calculated by using CalcuSyn software (Biosoft,
Cambridge, UK). Combination Index (CI) less than 1 was considered as synergistic. All
FACS data were collected on a BD Fortessa analyzer (BD Biosciences, CA, USA) and data
analyses performed using Flowjo software (Tree Star, OR, USA).
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tGLI2 overexpression
Myc-GLI2-DN (17649, pCS2-MT-GLI2-deltaN) plasmid was purchased from Addgene
(Cambridge, MA, USA). 3xHA-Gli2-FL plasmid was kindly provided by Philip Beachy
(Stanford). Plasmid transfection was performed using Turbofect transfection reagent
(#R0531, Thermo Scientific) according to the manufacturer's instructions. Cells were treated
with drugs 24hr post-transfection as indicated.
Western blot
Cells were lysed with RIPA buffer (sc-24948, Santa Cruz Biotechnology) for 30min on ice
and lysates cleared by centrifugation at 13000rpm, 15min at 4°C. Supernatants were
incubated with 4x Lamelli sample buffer (#161-0747, Bio-rad) at 95°C for 5min. The
samples were then separated with SDS-PAGE gel and immunoblotted with the indicated
antibodies: anti-HA (ab18181, Abcam), anti-c-Myc (sc-789, Santa Cruz Biotechnology),
anti-GLI1 (#2643, Cell signaling), anti-β-tubulin (ab6046, Abcam).
Lentiviral infection
shRNA lentiviral constructs against mouse Brd2/Brd3/Brd4 (The RNAi Consortium mouse
collection) were kindly provided by Alejandro Sweet-Cordero (Stanford) and shRNA
insertion sequences confirmed by Sanger sequencing. To produce shRNA lentivirus, 293T
cells were transfected with lentiviral vector and packaging plasmids (pDelta 8.92+VSV-G).
Titres were collected 48hr post-transfection and concentrated by PEG precipitation. The
precipitated lentivirus was resuspended in PBS and aliquoted for storage at -80°C. For
shRNA lentivirus infection, cells were incubated with shRNA lentivirus for 16hr. At 48hrs
post-infection, puromycin was added to select virally-infected cells for further experiments.
Dual-luciferase reporter assay
Hh-Light2 cells were cultured until confluent and treated with drug as indicated. Dual-
luciferase reporter assays were performed using the Dual-Luciferase Reporter Assay System
10-Pack (E1960, Promega, WI, USA) according to manufacturer's instructions and data
collected on a TECAN Infinite 200 plate reader.
ChIP-qPCR
Cells were fixed with 1% formaldehyde for 10min at room temperature before adding
Glycine to stop the fixation. The cells were then harvested and snap frozen and stored at
-80°C prior to use. For each Chromatin IP experiment, chromatin isolated from 10E6 to
10E7 cells was sonicated and immunoprecipitated with 3-5ug of the indicated antibody and
100ul Dynabeads protein G. Beads were washed five times with RIPA buffer and one time
with TE containing 50mM NaCl. Bound complexes were eluted by heating at 65°C with
occasional vortexing for 30min, and crosslinking was reversed by overnight incubation at
65°C. INPUT DNA was also treated for crosslink reversal. Immunoprecipitated DNA and
INPUT DNA were then purified by RNaseA/proteinase K treatment, phenol:chloroform
extraction and ethanol precipitation. qPCR was performed using 2x Maxima SYBR Green
qPCR Master Mix (#K0251, Thermo Scientific) on an Eppendorf Mastercycler PCR
machine. ChIP-qPCR primer sequences are listed in Supplemental Table 2.
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Gene expression data was generated from total RNA derived from biological duplicates of
SmoWT-MB cells treated with control (DMSO), JQ1 (1uM) or GDC-0449 (0.1uM) for 6hrs.
RNA was hybridized to Illumina MouseWG-6 v2.0 (SmoWT-MB) expression bead arrays
per the manufacturer's instructions. Rank-invariant normalized data was generated using
GenomeStudio v1.9.0 and converted to .gct file format, which was then collapsed to gene
symbols using the GSEA desktop application (http://www.broadinstitute.org/gsea/index.jsp).
Differentially expressed genes were visualized using the GENE-E desktop application
(http://www.broadinstitute.org/cancer/software/GENE-E/) and the top 5000 differentially
expressed genes between drug-treated and control-treated cells were used for agglomerative
heierarchical clustering using Pearson correlation and average linkage metric across samples
and genes.
Comparative marker selection analysis between JQ1 or GDC-0449 and DMSO treated cells
was performed in GenePattern using the default settings. Genes with a p value of less than
0.05 and a q-value value of less than 0.1 were considered to be significantly differentially
expressed. We performed Chi-square analysis to determine the significance of overlap
between genes that were down-regulated by JQ1 and GDC-0449. To identify gene sets
differentially expressed following treatment with JQ1 or GDC-0449 (compared to DMSO
controls), Gene set enrichment analysis (GSEA) was performed as previously described61
using the C2cpg gene set (MSigDB). Gene sets with a nominal p-value less than 0.05 and q
–value of less than 0.25 were considered significant. We performed Fisher's exact test to
determine the significance of overlap between gene sets that were down-regulated by JQ1
and GDC-0449.
GSEA was also performed using gene sets (.gmt files) derived from Puissant et al.46,
Atwood et al.34 and Lee et al.58 (Supplemental Table S1). Briefly, genes associated with
Gli1 ChIP-chip peaks in normal granule neuron precursor cells and medulloblastoma (listed
in Tables S1A and S1B from Lee et al.58) were converted to gene sets (“Lee_Gli1_GNP”
and “Lee_Gli1_MB”). We then used the Venn diagram function in GENE-E to generate
gene sets of overlapping and distinct genes between these lists (“Lee_Gli1_GNP_only”,
“Lee_Gli1_MB_only” and “Lee_Gli1_GNP_MB_overlap”).
In vivo mouse studies
In vivo efficacy studies were performed in accordance with protocols approved by the
Institutional Animal Care and Use Committee at Stanford University and Children's
Hospital Research Center Oakland. “SMOi-naïve” BCC allografts were derived from BCC
tumors generated in Ptch+/−;K14-creER2;p53flox/flox mice as previously described34. Tumors
were treated with vehicle control, BMS-833293 (Bristol Myers Squib Hedgehog inhibitor)
[100 mg/kg IP qd] or JQ1 [50 mg/kg IP qd], until euthanasia was required when the size of
vehicle-treated tumors exceeded the limit in our animal care guidelines. Tumor size was
measured with calipers every 3 to 4 days. Tumors were also harvested for RNA analysis.
SMOi-resistant mBCCs were generated by treating “SMOi-naïve” BCC allografts with
BMS-833293 in a cyclical fashion and then treated with JQ1 as described above. The tumors
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twere treated with JQ1 [50 mg/kg IP qd] or vehicle for 7 days before harvesting for RNA
analysis.
For in vivo medulloblastoma studies, SmoWT-MB, SmoD477G-MB and GFP-luc
transduced Med1-MB cells were used for flank or cerebellum injections. 2x10e6 cells were
injected into the flank of each 4-6 week old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mouse (The Jackson Laboratories). 0.5x10e6 cells were used for cerebellum injection, as
previously described32. After engraftments were confirmed, mice were randomized into
treatment and control groups and treated with vehicle control, GDC-0449 [100 mg/kg PO
qd] or JQ1 [50 mg/kg IP qd], until euthanasia was required. Tumor growth was measured
with calipers or monitored by IVIS imaging on a Xenogen IVIS2000 (Perkin-Elmer). At the
end of treatment, tumors were harvested in RNAlater for RNA analysis. Survival data was
recorded for the cerebellum injected mice using Med1-MB cells.
Zebrafish studies
Zebrafish embryos from an outcross of Tg(GBS-ptch2:EGFP)+/− with TL wild-type were
exposed to JQ1 at concentrations ranging from 0.25uM-5uM. A 0.6uM working dose was
determined optimal for in vivo studies as it caused no phenotype in contrast to 0.75uM,
which caused elevated cell death and dysmorphology. The ptch2:GFP reporter fish were
then exposed to JQ1, cyclopamine (25 uM), or vehicle control (DMSO or EtOH, for JQ1
and cyclopamine, respectively) from 2-30 hpf and then fixed with 4% paraformaldehyde for
in situ hybridization using a GFP probe and fast red. All fish with GFP positivity were
scored for intensity of staining.
For Shh overexpression experiments, embryos from an Tg(hsp70l:shha-EGFP)+/− x TL
wild-type were collected and heat shocked (HS) at 38ûC for 15 min at 8 somite stage.
Following HS, the embryos were immediately placed in JQ1 at 0.6 um or 6.0 um
concentrations. DMSO was used as a negative control. At 12 hpf GFP-positive and negative
embryos were sorted and embryos transferred to equivalent concentrations of fresh drug/
DMSO. Images were captured using a Nikon Coolpix digital P520 camera fitted to a Lieca
MZLIII stereo microscope at 30 and 56 hpf. Embryos were scored for eye size (dorsal axis
length) at 56hpf.
Statistical analysis
Two-way ANOVA test was used for comparing tumor growth curves. Log-rank test was
used for comparing survival curves. Chi-square test or Fisher's exact test were used for
statistical analysis of contingency table data. Student's t-test was used for all the other
comparisons.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1.
BRD4 is necessary for GLI transcription. (a) Gli-luciferase reporter activity in Hh-Light2
cells treated with Hh ligand (Shh-N CM or SAG) alone or in combination with increasing
amount of JQ1. Data represent mean of triplicates ± SD. (b) Quantitative RT-PCR of Hh
target genes (Gli1, Gli2, Ptch1), Hh pathway components (Sufu, Smo) and Brd4 in Hh-
Light2 cells treated with Hh ligand (Shh-N CM or SAG) alone or in combination with JQ1
(1uM). Data represent mean of triplicates ± SD. (c) Quantitative RT-PCR of Gli1 mRNA in
Hh-Light2 cells treated with Hh ligand (Shh-N CM or SAG) alone or in combination with
1uM of JQ1, GDC-0449, LDE225 or SANT-1. Data represent mean of triplicates ± SD. (d)
Immunoblot detecting Gli1 expression in cell lysates from Hh-Light2 cells treated with Hh
ligand (Shh-N CM or SAG) alone or in combination with 1uM of JQ1, GDC-0449, LDE225
or SANT-1. Anti-β-tubulin immunoblot shown as loading control. (e) Gli-luciferase reporter
activity in Hh-Light2 cells treated with Hh ligand (Shh-N CM or SAG) in combination with
shRNAs against Brd4 (shBrd4s) or scrambled shRNA (shCtrl). Data represent mean of
quadruplicates ± SD. (f) Quantitative RT-PCR of Hh target genes (Gli1, Gli2, Ptch1), Hh
pathway components (Sufu, Smo) and Brd4 upon treatment with Hh ligand (Shh-N CM or
SAG) alone or in combination with shBrd4s or shCtrl. Data represent mean of triplicates ±
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tSD. (g) In situ hybridization detecting GFP mRNA levels in transgenic zebrafish (ptc2:GFP)
treated with JQ1 (0.6uM), cyclopamine (25uM) or vehicle controls (DMSO or EtOH). The
fraction with decreased GFP expression was presented. Fisher's exact test was used for
statistical analysis. *p<0.05, scale bar = 100 micron. (h) Images of heat-shocked
+Tg(hsp70l:Shha-EGFP) or non-transgenic sibling treated with JQ1 (0.6uM) or DMSO. Eye
diameter of each group (n=12) was measured and presented. Data represent group means ±
SD, p-value generated using student's t-test. Scale bar = 100 micron.
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tFigure 2.
JQ1 inhibits Hh target gene activation at the level of the GLI1 and GLI2 promoters. (a)
Quantitative RT-PCR showing Gli1, Gli2, Smo and Brd4 mRNA levels in Sufu−/− MEFs
treated with JQ1. Data represent mean of triplicates ± SD. (b) Gli1/Gli2 mRNA levels in
Sufu−/− MEFs treated with DMSO, JQ1, GDC-0449, LDE225 or SANT-1. Data represent
mean of triplicates ± SD. (c) Immunoblot detecting GLI1 expression in cell lysates from
Sufu−/− MEFs treated with DMSO, JQ1, GDC-0449, LDE225 or SANT-1. Anti-β-tubulin
immunoblot shown as loading control. (d) Quantitative RT-PCR showing Gli1, Gli2 and
Brd4 mRNA levels in Sufu−/− cells expressing shBrd4s or shCtrl. Data represent mean of
triplicates ± SD. (e) Quantitative RT-PCR showing Gli1 mRNA levels in Hh-Light2 cells
transiently transfected with full length Gli2 (HA-Gli2-FL) or N-terminally truncated GLI2
(Myc-GLI2-DN) and their responses to JQ1, GDC-0449, LDE225 or SANT-1. Data
represent mean of triplicates ± SD. (f) Anti-HA and anti-Myc immunoblots on cell lysates
from Hh-Light2 cells transfected with HA-Gli2-FL or Myc-GLI2-DN and treated with
DMSO, JQ1, GDC-0449, LDE225 or SANT-1. Anti-β-tubulin immunoblot shown as
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tloading control. Schematic of regions flanking the Gli1 and Gli2 promoter transcription start
sites analyzed by ChIP-qPCR of Brd4 and PolII occupancies in Hh-Light2 cells treated with
SAG and JQ1 (g,h) and in Sufu−/− MEFs treated with JQ1 (i,j). Data represent mean of
triplicates ± SD. Except where indicated, cells were treated with 1 uM of JQ1, GDC-0449,
LDE225 or SANT-1.
Tang et al. Page 20
Nat Med. Author manuscript; available in PMC 2015 January 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 3.
JQ1 inhibits Hh pathway activity and cell viability and proliferation in Ptch-mutated
medulloblastoma (MB, SmoWT-MB and Med1-MB) cells. (a,b) Quantitative RT-PCR of
expressions of Hh pathway target genes (Gli1, Gli2), components (Smo and Sufu) and Brd4
in SmoWT-MB and Med1-MB cells treated with JQ1 (1 uM), GDC-0449 (0.1uM) or
LDE225 (0.1uM). Data represent mean of triplicates ± SD. (c,d) Immunoblot detecing Gli1
expression in response to JQ1 treatment over time. Anti-β-tubulin immunoblot shown as
loading control. (e,f) Cell viability detection over time with increasing doses of JQ1 or SMO
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tinhibitors. Data represent group means ± SD. (g,h) Proliferative index in response to JQ1 (1
uM) or SMO inhibitors (GDC-0449 or LDE225 at 0.1uM) as measured by EdU
incorporation. Data represent group means ± SD.
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On-target validation of JQ1's inhibitory effects in Hh-driven tumor cells. Quantitative RT-
PCR of Gli1, Gli2 and Brd4 mRNAs (a,b) and proliferative index determined by EdU
incorporation (c,d) in shBrd4s or shCtrl expressing medulloblastoma tumor cells (SmoWT-
MB and Med1-MB). Data represent group means ± SD. (e) The schematic workflow of the
GLI2-overexpressing resuce experiment in SmoWT-MB cells. (f) FACS analysis of EdU
incorporation in SmoWT-MB cells transfected with empty vector or Myc-GLI2-DN
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tfollowed by JQ1 treatment (0.1uM or 0.5uM). GFP-expressing plasmid was used for co-
transfection to mark the transfected (GFP+) cells.
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tFigure 5.
JQ1 inhibits Hh pathway activity and cell viability and proliferation in SMOi-resistant Hh-
driven tumors. (a) Schematic depicting mechanisms of resistance to Smoothened antagonists
in Hh-driven cancers. Cell viability in (b) SMOi-resistant medulloblastoma cells
(SmoD477G-MB), (c) patient-derived SUFU mutant medulloblastoma cells (RCMB025),
(d,e) patient-derived ATRT cells (CHB_ATRT1 and SU_ATRT2) and (f) patient-derived
MYCN-amplified medulloblastoma cells (RCMB018) treated with increasing doses of JQ1,
GDC-0449 or LDE225. Data represent group means ± SD. Quantitative RT-PCR of Gli1/
GLI1, Gli2/GLI2 and Brd4/BRD4 (plus MYC and MYCN levels for RCMB018) in
SmoD477G-MB (g), RCMB025 (h), CHB_ATRT1 (i), SU_ATRT2 (j) and RCMB018 (k)
cells in response to JQ1 (1 uM), GDC-0449 or LDE225 (0.1uM for SmoD477G-MB and 1
uM for the others). Data represent mean of triplicates ± SD.
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tFigure 6.
JQ1 inhibits Hh-driven tumor growth in vivo. Med1-MB cells transduced with a lentiviral
luciferase reporter were used for flank (a) or cerebellum (b) injections of NSG mice, which
were then randomized for treatment with either JQ1 (50mg/kg daily, IP) or vehicle. (a)
Tumor growth of Med1-MB allografts was assessed by IVIS imaging and presented as
average radiance. (b) Survival curve of the cerebellum injected mice with Med1-MB cells.
(c) SmoWT-MB and (d) SmoD477G-MB cells were injected into the flanks of NSG mice
(both flanks of each mouse), followed by treatment with JQ1[50 mg/kg IP qd], GDC-0449
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t[100 mg/kg PO qd] or vehicle. Tumor growth was assessed by caliper measurement. (e)
SMOi-naïve mouse BCC tumors generated under the dermis of NSG mice were treated with
JQ1 (50 mg/kg daily, IP), BMS-833293 [100 mg/kg daily, IP] or vehicle. Tumor growth was
assessed by caliper measurement. Data of tumor growth represent group means ± S.E.M.
Two-way ANOVA test was used for comparing tumor growth curves. Log-rank test was
used for comparing survival curves.
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